Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

C3.ai's CEO and founder, Tom Siebel, has announced his decision to step down once a new CEO is in place. C3.ai could go two different ways with its CEO search. 10 stocks we like better than C3.ai › C3 ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

We've waited quite some time for a reasonable choice of affordable small electric cars, and while they’re not exactly coming ...

Alongside The Marías, Young Miko and Ca7riel & Paco Amoroso, the de la Rosa brothers made sure that Latin music was heard at ...

C3 Bullion, a pioneer in next-generation gold investment solutions, has launched its India operations, bringing its flagship ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion. McKinsey estimates that AI could generate up to $4.4 trillion in ...

Police and paramedics were called to the coastbound carriageway of the A299 near Herne Bay at about 10am. The force says four ...